Contents
Overview
Guerbet was founded in 1926 by André Guerbet, the son of Marcel Guerbet, who discovered Lipiodol, the first iodinated X-ray contrast agent, in 1901. This breakthrough discovery paved the way for the development of modern medical imaging, and Guerbet has been at the forefront of this field ever since, working with companies like General Electric Healthcare and Canon Medical Systems to advance imaging capabilities. Today, Guerbet is a leading manufacturer of contrast agents, with a portfolio of products that includes Lipiodol, Elucirem, and others, which are used in conjunction with imaging technologies like MRI and CT scans from companies like Toshiba Medical Systems and Hitachi Healthcare.
⚙️ Products & Technology
Guerbet's products are used in a wide range of medical imaging applications, from X-ray and computed tomography (CT) to magnetic resonance imaging (MRI) and ultrasound, and are often used in conjunction with technologies from companies like IBM Watson Health and Google Health. The company's contrast agents are designed to enhance image quality and provide clinicians with valuable diagnostic information, and are used by medical professionals around the world, including those at hospitals like Mayo Clinic and Cleveland Clinic. Guerbet's commitment to innovation has led to the development of new products like Elucirem, which was approved by the FDA in 2022, and is produced at the company's factory in Raleigh, North Carolina, using manufacturing technologies from companies like Siemens and Rockwell Automation.
🌍 Global Presence & Acquisitions
Guerbet has a significant global presence, with manufacturing facilities in France, Ireland, Canada, Macedonia, the United States, and Brazil, and a headquarters located in Chicago, which is also home to companies like Abbott Laboratories and Baxter International. The company employs over 2,700 people worldwide and has a strong reputation for quality and customer service, working with distributors like Cardinal Health and McKesson Corporation to get its products to market. In 2015, Guerbet acquired a portion of Mallinckrodt's contrast media and application systems divisions, which expanded the company's product portfolio and strengthened its position in the market, and has also partnered with companies like Microsoft Health and athenahealth to advance its digital capabilities.
🔮 Regulatory Approvals & Future Directions
Guerbet's regulatory approvals are a testament to the company's commitment to quality and safety, and the FDA approval of Elucirem in 2022 is a significant milestone for the company, which has also received approvals from regulatory agencies like the European Medicines Agency and the Japanese Ministry of Health, Labour and Welfare. As the medical imaging industry continues to evolve, Guerbet is well-positioned to remain a leader in the field, with a strong pipeline of new products and technologies in development, and is working with companies like Amazon Web Services and Intel Health to advance its capabilities in areas like artificial intelligence and cloud computing.
Key Facts
- Year
- 1926
- Origin
- France
- Category
- technology
- Type
- organization
Frequently Asked Questions
What is Guerbet's main product?
Guerbet's main products are contrast agents used in medical imaging, including Lipiodol and Elucirem.
Who founded Guerbet?
Guerbet was founded by André Guerbet in 1926.
What is the significance of Lipiodol?
Lipiodol is the first iodinated X-ray contrast agent, discovered by Marcel Guerbet in 1901.
What is Elucirem?
Elucirem is an MRI contrast agent developed by Guerbet, approved by the FDA in 2022.
Where is Guerbet's headquarters located?
Guerbet's headquarters is located in Chicago, Illinois, USA.